Calidi Biotherapeutics Files 8-K/A Amendment

Ticker: CLDWW · Form: 8-K/A · Filed: Feb 10, 2025 · CIK: 1855485

Calidi Biotherapeutics, Inc. 8-K/A Filing Summary
FieldDetail
CompanyCalidi Biotherapeutics, Inc. (CLDWW)
Form Type8-K/A
Filed DateFeb 10, 2025
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: amendment, financial-statements, exhibits

TL;DR

Calidi Biotherapeutics filed an 8-K/A amendment on Feb 10, 2025, updating financial statements and exhibits.

AI Summary

Calidi Biotherapeutics, Inc. filed an 8-K/A amendment on February 10, 2025, to report financial statements and exhibits. This filing amends a previous report and provides updated information regarding the company's financial status and operational disclosures.

Why It Matters

This amendment provides updated financial and exhibit information, which is crucial for investors to assess the company's current financial health and any material changes.

Risk Assessment

Risk Level: low — This filing is an amendment to report financial statements and exhibits, not a material event like an acquisition or new debt.

Key Players & Entities

  • Calidi Biotherapeutics, Inc. (company) — Registrant
  • February 10, 2025 (date) — Filing Date
  • Delaware (jurisdiction) — State of Incorporation
  • San Diego, California (location) — Principal Executive Offices
  • First Light Acquisition Group, Inc. (company) — Former Company Name

FAQ

What is the purpose of this 8-K/A filing?

The purpose of this 8-K/A filing is to amend a previous report and provide updated financial statements and exhibits for Calidi Biotherapeutics, Inc.

When was this amendment filed?

This amendment was filed on February 10, 2025.

What is the principal business address of Calidi Biotherapeutics, Inc.?

The principal business address is 4475 Executive Drive, Suite 200, San Diego, California 92121.

What was the former name of Calidi Biotherapeutics, Inc.?

The former name was First Light Acquisition Group, Inc., with a date of name change on April 6, 2021.

What is the SIC code for Calidi Biotherapeutics, Inc.?

The Standard Industrial Classification (SIC) code is 2836, for BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).

Filing Stats: 515 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2025-02-10 17:28:12

Key Financial Figures

  • $0.0001 — ch Registered Common stock, par value $0.0001 per share CLDI NYSE American LLC

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CALIDI BIOTHERAPEUTICS, INC. Dated: February 10, 2025 By: /s/ Andrew Jackson Name: Andrew Jackson Title: Chief Financial Officer

View Full Filing

View this 8-K/A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.